Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 325455
  • calendar_today Published On: Jan, 2023
  • file_copy Pages: 165
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Corticosteroid Therapy segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) include Teijin Pharma, Shire, Pfizer, Octapharma, and Momenta Pharmaceuticals, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Corticosteroid Therapy

IVIG Treatment

Plasma Exchange Therapy

Immunosuppressive Drug Therapy

Immunomodulator Therapy

Other

Market segment by Application, can be divided into

Hospital

Specialist Neurology Clinic

Research and Academic Laboratories

Market segment by players, this report covers

Teijin Pharma

Shire

Pfizer

Octapharma

Momenta Pharmaceuticals

Mitsubishi Tanabe Pharma Corporation

Kedrion

Grifols

CSL Behring (CSL Limited)

Bio Products Laboratory

Baxter

MedDay Pharmaceuticals

GeNeuro Pharmaceuticals

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with revenue, gross margin and global market share of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) from 2019 to 2022.

Chapter 3, the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

1.2 Classification of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Type

1.2.1 Overview: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type in 2021

1.2.3 Corticosteroid Therapy

1.2.4 IVIG Treatment

1.2.5 Plasma Exchange Therapy

1.2.6 Immunosuppressive Drug Therapy

1.2.7 Immunomodulator Therapy

1.2.8 Other

1.3 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market by Application

1.3.1 Overview: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hospital

1.3.3 Specialist Neurology Clinic

1.3.4 Research and Academic Laboratories

1.4 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size & Forecast

1.5 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast by Region

1.5.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region, (2017-2022)

1.5.3 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Prospect (2017-2028)

1.5.4 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Prospect (2017-2028)

1.5.6 South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Drivers

1.6.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Restraints

1.6.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trends Analysis

2 Company Profiles

2.1 Teijin Pharma

2.1.1 Teijin Pharma Details

2.1.2 Teijin Pharma Major Business

2.1.3 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

2.1.4 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Teijin Pharma Recent Developments and Future Plans

2.2 Shire

2.2.1 Shire Details

2.2.2 Shire Major Business

2.2.3 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

2.2.4 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Shire Recent Developments and Future Plans

2.3 Pfizer

2.3.1 Pfizer Details

2.3.2 Pfizer Major Business

2.3.3 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

2.3.4 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Pfizer Recent Developments and Future Plans

2.4 Octapharma

2.4.1 Octapharma Details

2.4.2 Octapharma Major Business

2.4.3 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

2.4.4 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Octapharma Recent Developments and Future Plans

2.5 Momenta Pharmaceuticals

2.5.1 Momenta Pharmaceuticals Details

2.5.2 Momenta Pharmaceuticals Major Business

2.5.3 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

2.5.4 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Momenta Pharmaceuticals Recent Developments and Future Plans

2.6 Mitsubishi Tanabe Pharma Corporation

2.6.1 Mitsubishi Tanabe Pharma Corporation Details

2.6.2 Mitsubishi Tanabe Pharma Corporation Major Business

2.6.3 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

2.6.4 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Mitsubishi Tanabe Pharma Corporation Recent Developments and Future Plans

2.7 Kedrion

2.7.1 Kedrion Details

2.7.2 Kedrion Major Business

2.7.3 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

2.7.4 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Kedrion Recent Developments and Future Plans

2.8 Grifols

2.8.1 Grifols Details

2.8.2 Grifols Major Business

2.8.3 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

2.8.4 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Grifols Recent Developments and Future Plans

2.9 CSL Behring (CSL Limited)

2.9.1 CSL Behring (CSL Limited) Details

2.9.2 CSL Behring (CSL Limited) Major Business

2.9.3 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

2.9.4 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 CSL Behring (CSL Limited) Recent Developments and Future Plans

2.10 Bio Products Laboratory

2.10.1 Bio Products Laboratory Details

2.10.2 Bio Products Laboratory Major Business

2.10.3 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

2.10.4 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Bio Products Laboratory Recent Developments and Future Plans

2.11 Baxter

2.11.1 Baxter Details

2.11.2 Baxter Major Business

2.11.3 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

2.11.4 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Baxter Recent Developments and Future Plans

2.12 MedDay Pharmaceuticals

2.12.1 MedDay Pharmaceuticals Details

2.12.2 MedDay Pharmaceuticals Major Business

2.12.3 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

2.12.4 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 MedDay Pharmaceuticals Recent Developments and Future Plans

2.13 GeNeuro Pharmaceuticals

2.13.1 GeNeuro Pharmaceuticals Details

2.13.2 GeNeuro Pharmaceuticals Major Business

2.13.3 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

2.13.4 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 GeNeuro Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players Market Share in 2021

3.2.2 Top 10 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players Head Office, Products and Services Provided

3.4 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Mergers & Acquisitions

3.5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Market Share by Type (2017-2022)

4.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Application (2017-2022)

5.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type (2017-2028)

6.2 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2017-2028)

6.3 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country

6.3.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Country (2017-2028)

6.3.2 United States Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

6.3.3 Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

6.3.4 Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type (2017-2028)

7.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2017-2028)

7.3 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country

7.3.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Country (2017-2028)

7.3.2 Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

7.3.3 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

7.3.5 Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

7.3.6 Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type (2017-2028)

8.2 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2017-2028)

8.3 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region

8.3.1 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Region (2017-2028)

8.3.2 China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

8.3.3 Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

8.3.4 South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

8.3.5 India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

8.3.7 Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type (2017-2028)

9.2 South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2017-2028)

9.3 South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country

9.3.1 South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Country (2017-2028)

9.3.2 Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

9.3.3 Argentina Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type (2017-2028)

10.2 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2017-2028)

10.3 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country

10.3.1 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Country (2017-2028)

10.3.2 Turkey Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

10.3.4 UAE Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million) by Region (2017-2022)

Table 5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Region (2023-2028)

Table 6. Teijin Pharma Corporate Information, Head Office, and Major Competitors

Table 7. Teijin Pharma Major Business

Table 8. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

Table 9. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Shire Corporate Information, Head Office, and Major Competitors

Table 11. Shire Major Business

Table 12. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

Table 13. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Pfizer Corporate Information, Head Office, and Major Competitors

Table 15. Pfizer Major Business

Table 16. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

Table 17. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Octapharma Corporate Information, Head Office, and Major Competitors

Table 19. Octapharma Major Business

Table 20. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

Table 21. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Momenta Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 23. Momenta Pharmaceuticals Major Business

Table 24. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

Table 25. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Mitsubishi Tanabe Pharma Corporation Corporate Information, Head Office, and Major Competitors

Table 27. Mitsubishi Tanabe Pharma Corporation Major Business

Table 28. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

Table 29. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Kedrion Corporate Information, Head Office, and Major Competitors

Table 31. Kedrion Major Business

Table 32. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

Table 33. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Grifols Corporate Information, Head Office, and Major Competitors

Table 35. Grifols Major Business

Table 36. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

Table 37. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. CSL Behring (CSL Limited) Corporate Information, Head Office, and Major Competitors

Table 39. CSL Behring (CSL Limited) Major Business

Table 40. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

Table 41. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Bio Products Laboratory Corporate Information, Head Office, and Major Competitors

Table 43. Bio Products Laboratory Major Business

Table 44. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

Table 45. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Baxter Corporate Information, Head Office, and Major Competitors

Table 47. Baxter Major Business

Table 48. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

Table 49. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. MedDay Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 51. MedDay Pharmaceuticals Major Business

Table 52. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

Table 53. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. GeNeuro Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 55. GeNeuro Pharmaceuticals Major Business

Table 56. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions

Table 57. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 59. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 60. Breakdown of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Company Type (Tier 1, Tier 2 and Tier 3)

Table 61. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players Head Office, Products and Services Provided

Table 62. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Mergers & Acquisitions in the Past Five Years

Table 63. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) New Entrants and Expansion Plans

Table 64. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million) by Type (2017-2022)

Table 65. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Type (2017-2022)

Table 66. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Forecast by Type (2023-2028)

Table 67. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2017-2022)

Table 68. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Forecast by Application (2023-2028)

Table 69. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type (2017-2022) & (USD Million)

Table 70. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type (2023-2028) & (USD Million)

Table 71. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2017-2022) & (USD Million)

Table 72. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2023-2028) & (USD Million)

Table 73. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Country (2017-2022) & (USD Million)

Table 74. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Country (2023-2028) & (USD Million)

Table 75. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type (2017-2022) & (USD Million)

Table 76. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type (2023-2028) & (USD Million)

Table 77. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2017-2022) & (USD Million)

Table 78. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2023-2028) & (USD Million)

Table 79. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Country (2017-2022) & (USD Million)

Table 80. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Country (2023-2028) & (USD Million)

Table 81. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type (2017-2022) & (USD Million)

Table 82. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type (2023-2028) & (USD Million)

Table 83. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2017-2022) & (USD Million)

Table 84. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2023-2028) & (USD Million)

Table 85. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Region (2017-2022) & (USD Million)

Table 86. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Region (2023-2028) & (USD Million)

Table 87. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type (2017-2022) & (USD Million)

Table 88. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type (2023-2028) & (USD Million)

Table 89. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2017-2022) & (USD Million)

Table 90. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2023-2028) & (USD Million)

Table 91. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Country (2017-2022) & (USD Million)

Table 92. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Country (2023-2028) & (USD Million)

Table 93. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type (2017-2022) & (USD Million)

Table 94. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type (2023-2028) & (USD Million)

Table 95. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2017-2022) & (USD Million)

Table 96. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2023-2028) & (USD Million)

Table 97. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Country (2017-2022) & (USD Million)

Table 98. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Picture

Figure 2. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type in 2021

Figure 3. Corticosteroid Therapy

Figure 4. IVIG Treatment

Figure 5. Plasma Exchange Therapy

Figure 6. Immunosuppressive Drug Therapy

Figure 7. Immunomodulator Therapy

Figure 8. Other

Figure 9. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Application in 2021

Figure 10. Hospital Picture

Figure 11. Specialist Neurology Clinic Picture

Figure 12. Research and Academic Laboratories Picture

Figure 13. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 14. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Forecast (2017-2028) & (USD Million)

Figure 15. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Region (2017-2028)

Figure 16. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Region in 2021

Figure 17. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 21. Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 22. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Drivers

Figure 23. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Restraints

Figure 24. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends

Figure 25. Teijin Pharma Recent Developments and Future Plans

Figure 26. Shire Recent Developments and Future Plans

Figure 27. Pfizer Recent Developments and Future Plans

Figure 28. Octapharma Recent Developments and Future Plans

Figure 29. Momenta Pharmaceuticals Recent Developments and Future Plans

Figure 30. Mitsubishi Tanabe Pharma Corporation Recent Developments and Future Plans

Figure 31. Kedrion Recent Developments and Future Plans

Figure 32. Grifols Recent Developments and Future Plans

Figure 33. CSL Behring (CSL Limited) Recent Developments and Future Plans

Figure 34. Bio Products Laboratory Recent Developments and Future Plans

Figure 35. Baxter Recent Developments and Future Plans

Figure 36. MedDay Pharmaceuticals Recent Developments and Future Plans

Figure 37. GeNeuro Pharmaceuticals Recent Developments and Future Plans

Figure 38. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Players in 2021

Figure 39. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 40. Global Top 3 Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share in 2021

Figure 41. Global Top 10 Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share in 2021

Figure 42. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 43. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Type in 2021

Figure 44. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share Forecast by Type (2023-2028)

Figure 45. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Application in 2021

Figure 46. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share Forecast by Application (2023-2028)

Figure 47. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Market Share by Type (2017-2028)

Figure 48. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Market Share by Application (2017-2028)

Figure 49. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Country (2017-2028)

Figure 50. United States Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Market Share by Type (2017-2028)

Figure 54. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Market Share by Application (2017-2028)

Figure 55. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Country (2017-2028)

Figure 56. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. United Kingdom Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Market Share by Type (2017-2028)

Figure 62. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Market Share by Application (2017-2028)

Figure 63. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Region (2017-2028)

Figure 64. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Market Share by Type (2017-2028)

Figure 71. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Market Share by Application (2017-2028)

Figure 72. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Country (2017-2028)

Figure 73. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. Argentina Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Market Share by Type (2017-2028)

Figure 76. Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Market Share by Application (2017-2028)

Figure 77. Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Country (2017-2028)

Figure 78. Turkey Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 79. Saudi Arabia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. UAE Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. Methodology

Figure 82. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz